These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
378 related articles for article (PubMed ID: 37241929)
41. Risk factors of colorectal cancer in inflammatory bowel disease. Bansal P; Sonnenberg A Am J Gastroenterol; 1996 Jan; 91(1):44-8. PubMed ID: 8561142 [TBL] [Abstract][Full Text] [Related]
42. Patients' knowledge and fear of colorectal cancer risk in inflammatory bowel disease. Lopez A; Collet-Fenetrier B; Belle A; Peyrin-Biroulet L J Dig Dis; 2016 Jun; 17(6):383-91. PubMed ID: 27129893 [TBL] [Abstract][Full Text] [Related]
43. NLRP3 Inhibitors as Potential Therapeutic Agents for Treatment of Inflammatory Bowel Disease. Perera AP; Kunde D; Eri R Curr Pharm Des; 2017; 23(16):2321-2327. PubMed ID: 28155620 [TBL] [Abstract][Full Text] [Related]
44. Effects of Wine Components in Inflammatory Bowel Diseases. Vrdoljak J; Kumric M; Ticinovic Kurir T; Males I; Martinovic D; Vilovic M; Bozic J Molecules; 2021 Sep; 26(19):. PubMed ID: 34641434 [TBL] [Abstract][Full Text] [Related]
45. Recent advances on emerging nanomaterials for diagnosis and treatment of inflammatory bowel disease. Fu W; Xu L; Chen Z; Kan L; Ma Y; Qian H; Wang W J Control Release; 2023 Nov; 363():149-179. PubMed ID: 37741461 [TBL] [Abstract][Full Text] [Related]
46. Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease. Brackmann S; Andersen SN; Aamodt G; Langmark F; Clausen OP; Aadland E; Fausa O; Rydning A; Vatn MH Scand J Gastroenterol; 2009; 44(1):46-55. PubMed ID: 18609187 [TBL] [Abstract][Full Text] [Related]
47. Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk? Dyson JK; Rutter MD World J Gastroenterol; 2012 Aug; 18(29):3839-48. PubMed ID: 22876036 [TBL] [Abstract][Full Text] [Related]
48. Occurrence of Colorectal Cancer and the Influence of Medical Treatment in Patients With Inflammatory Bowel Disease: A Danish Nationwide Cohort Study, 1997 to 2015. Weimers P; Ankersen DV; Løkkegaard ECL; Burisch J; Munkholm P Inflamm Bowel Dis; 2021 Oct; 27(11):1795-1803. PubMed ID: 33409534 [TBL] [Abstract][Full Text] [Related]
49. Mango (Mangifera indica L.) polyphenols reduce IL-8, GRO, and GM-SCF plasma levels and increase Lactobacillus species in a pilot study in patients with inflammatory bowel disease. Kim H; Venancio VP; Fang C; Dupont AW; Talcott ST; Mertens-Talcott SU Nutr Res; 2020 Mar; 75():85-94. PubMed ID: 32109839 [TBL] [Abstract][Full Text] [Related]
50. Does aspirin or non-aspirin non-steroidal anti-inflammatory drug use prevent colorectal cancer in inflammatory bowel disease? Burr NE; Hull MA; Subramanian V World J Gastroenterol; 2016 Apr; 22(13):3679-86. PubMed ID: 27053860 [TBL] [Abstract][Full Text] [Related]
51. Natural products as a source of anti-inflammatory agents associated with inflammatory bowel disease. Debnath T; Kim DH; Lim BO Molecules; 2013 Jun; 18(6):7253-70. PubMed ID: 23783459 [TBL] [Abstract][Full Text] [Related]
52. Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases. Li Y; Chen J; Bolinger AA; Chen H; Liu Z; Cong Y; Brasier AR; Pinchuk IV; Tian B; Zhou J Inflamm Bowel Dis; 2021 Nov; 27(Suppl 2):S38-S62. PubMed ID: 34791293 [TBL] [Abstract][Full Text] [Related]
53. Bacterial β-(1,3)-glucan prevents DSS-induced IBD by restoring the reduced population of regulatory T cells. Lee KH; Park M; Ji KY; Lee HY; Jang JH; Yoon IJ; Oh SS; Kim SM; Jeong YH; Yun CH; Kim MK; Lee IY; Choi HR; Ko KS; Kang HS Immunobiology; 2014 Oct; 219(10):802-12. PubMed ID: 25092569 [TBL] [Abstract][Full Text] [Related]
54. Implications of lymphatic alterations in the pathogenesis and treatment of inflammatory bowel disease. Zhang L; Ocansey DKW; Liu L; Olovo CV; Zhang X; Qian H; Xu W; Mao F Biomed Pharmacother; 2021 Aug; 140():111752. PubMed ID: 34044275 [TBL] [Abstract][Full Text] [Related]
55. Temporal trend in inpatient mortality in inflammatory bowel disease-associated colorectal cancer vs non-inflammatory colorectal cancer: a nationwide retrospective study. Flores E; Mbachi C; Achebe I; Asotibe J; Palomera-Tejeda E; Vohra I; Udechukwu V; Kotwal V Int J Colorectal Dis; 2021 Apr; 36(4):701-708. PubMed ID: 33063223 [TBL] [Abstract][Full Text] [Related]
56. Clinical features of bowel disease in patients aged <50 years in primary care: a large case-control study. Stapley SA; Rubin GP; Alsina D; Shephard EA; Rutter MD; Hamilton WT Br J Gen Pract; 2017 May; 67(658):e336-e344. PubMed ID: 28347985 [TBL] [Abstract][Full Text] [Related]
57. Polysaccharides as Carriers of Polyphenols: Comparison of Freeze-Drying and Spray-Drying as Encapsulation Techniques. Buljeta I; Pichler A; Šimunović J; Kopjar M Molecules; 2022 Aug; 27(16):. PubMed ID: 36014306 [TBL] [Abstract][Full Text] [Related]
58. Effects of Olive Oil and Its Components on Intestinal Inflammation and Inflammatory Bowel Disease. Vrdoljak J; Kumric M; Vilovic M; Martinovic D; Tomic IJ; Krnic M; Ticinovic Kurir T; Bozic J Nutrients; 2022 Feb; 14(4):. PubMed ID: 35215407 [TBL] [Abstract][Full Text] [Related]
59. Inflammatory pathways of importance for management of inflammatory bowel disease. Pedersen J; Coskun M; Soendergaard C; Salem M; Nielsen OH World J Gastroenterol; 2014 Jan; 20(1):64-77. PubMed ID: 24415859 [TBL] [Abstract][Full Text] [Related]
60. Pharmacological control of autophagy: therapeutic perspectives in inflammatory bowel disease and colorectal cancer. García-Mauriño S; Alcaide A; Domínguez C Curr Pharm Des; 2012; 18(26):3853-73. PubMed ID: 22632751 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]